Related Experiment Video

Updated: May 28, 2026

In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines
09:57

In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines

Published on: March 5, 2019

Dexamethasone induces fetal developmental toxicity through affecting the placental glucocorticoid barrier and

Dan Xu1, Man Chen, Xiao-liang Pan

  • 1Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071 China.

Environmental Toxicology and Pharmacology
|October 19, 2011
PubMed

Insights

Prenatal dexamethasone exposure causes intrauterine growth retardation (IUGR) in mice by disrupting maternal and fetal adrenal function. This study reveals a potential neuroendocrine-interference mechanism impacting fetal development.

Area of Science:

  • Endocrinology
  • Developmental Toxicology
  • Neuroendocrinology

Background:

  • Glucocorticoids like dexamethasone are crucial for fetal development.
  • Synthetic glucocorticoids can cause developmental toxicity through various mechanisms.
  • The neuroendocrine effects of prenatal dexamethasone exposure require further elucidation.

Purpose of the Study:

  • To investigate the neuroendocrine-interference mechanism of dexamethasone-induced developmental toxicity.
  • To evaluate the impact of prenatal dexamethasone on maternal and fetal adrenal function.
  • To assess the role of the placental glucocorticoid barrier in dexamethasone toxicity.

Main Methods:

  • Pregnant mice were administered varying doses of dexamethasone.
  • Maternal serum corticosterone levels were measured.
  • mRNA expression of steroidogenic acute regulatory protein (StAR) and P450scc in maternal and fetal adrenal glands, and placental 11β-HSD-2 were analyzed.
  • In vitro studies using human fetal adrenocortical cells were conducted.

Main Results:

  • Dexamethasone exposure led to dose-dependent intrauterine growth retardation (IUGR).
  • Maternal serum corticosterone levels decreased significantly post-dexamethasone treatment.
  • mRNA expression of maternal and fetal adrenal StAR and P450scc, and placental 11β-HSD-2 were reduced.
  • In vitro dexamethasone treatment did not alter StAR and P450scc expression.

Conclusions:

  • Prenatal dexamethasone exposure induces fetal developmental toxicity, primarily IUGR.
  • Dexamethasone may impair fetal development by affecting the placental glucocorticoid barrier and suppressing fetal adrenal function.
  • The neuroendocrine-interference mechanism involves downregulation of key steroidogenic enzymes in the adrenal glands.

More Related Videos

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings14:40

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings

Published on: October 25, 2015

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Hormones of the Adrenal Glands01:31

Hormones of the Adrenal Glands

Adrenal hormones play a pivotal role in maintaining the body's electrolyte balance and orchestrating responses to stress, showcasing the intricate functions of the adrenal cortex and medulla.
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and corticosterone...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...